• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[化脓性汗腺炎患者管理指南]

[Guidelines for the Management of Patients with Hidradenitis Suppurativa].

作者信息

Cabete Joana, Aparício Martins Inês

机构信息

Serviço de Dermatovenereologia. Hospital de Santo António dos Capuchos. Centro Hospitalar Universitário de Lisboa Central. Lisboa. Portugal.

出版信息

Acta Med Port. 2023 Feb 1;36(2):133-139. doi: 10.20344/amp.18916.

DOI:10.20344/amp.18916
PMID:36738185
Abstract

Hidradenitis suppurativa is a chronic and recurrent inflammatory dermatosis characterized by the presence of inflammatory nodules and abscesses in the apocrine gland-rich areas that may progress to suppurative fistulas and scars. Despite being considered one of the dermatological conditions with the greatest impact on patient quality of life, it is often underdiagnosed. Hidradenitis suppurativa, especially in its severe forms, is associated with numerous comorbidities, so a holistic and multidisciplinary perspective is crucial for the management of these patients. The therapeutic approach is complex and challenging. The medical treatment options are diverse and must be adapted to clinical presentation and disease severity. Surgical therapy should be considered as an adjuvant to medical treatment, particularly in refractory cases and in the presence of scars or anatomical and/or functional mutilation. These recommendations reflect the main aspects of the management of the patient with hidradenitis suppurativa and are addressed to all healthcare professionals who take part in their follow-up.

摘要

化脓性汗腺炎是一种慢性复发性炎症性皮肤病,其特征是在富含顶泌汗腺的区域出现炎性结节和脓肿,并可能发展为化脓性瘘管和瘢痕。尽管它被认为是对患者生活质量影响最大的皮肤病之一,但常常被漏诊。化脓性汗腺炎,尤其是严重形式,与多种合并症相关,因此整体和多学科的观点对于管理这些患者至关重要。治疗方法复杂且具有挑战性。药物治疗选择多样,必须根据临床表现和疾病严重程度进行调整。手术治疗应被视为药物治疗的辅助手段,特别是在难治性病例以及存在瘢痕或解剖和/或功能毁损的情况下。这些建议反映了化脓性汗腺炎患者管理的主要方面,并面向所有参与其随访的医疗保健专业人员。

相似文献

1
[Guidelines for the Management of Patients with Hidradenitis Suppurativa].[化脓性汗腺炎患者管理指南]
Acta Med Port. 2023 Feb 1;36(2):133-139. doi: 10.20344/amp.18916.
2
Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.皮肤科和性病科在莫斯塔尔临床医院用阿达木单抗治疗两例化脓性汗腺炎。
Acta Dermatovenerol Croat. 2021 Jul;29(2):108-110.
3
Managing patients with hidradenitis suppurativa.化脓性汗腺炎患者的管理
Practitioner. 2016 May;260(1793):25-9, 3.
4
[Acne inversa/hidradenitis suppurativa: An update].[化脓性汗腺炎/反向性痤疮:最新进展]
Hautarzt. 2017 Dec;68(12):999-1006. doi: 10.1007/s00105-017-4082-5.
5
Hidradenitis Suppurativa in Pediatric Patients.儿童化脓性汗腺炎。
Pediatrics. 2023 May 1;151(5). doi: 10.1542/peds.2022-061049.
6
[New therapeutic approaches for hidradenitis suppurativa].[化脓性汗腺炎的新治疗方法]
Rev Med Brux. 2018;39(4):367-371.
7
Practical Guidelines for Managing Patients With Hidradenitis Suppurativa: An Update.《化脓性汗腺炎患者管理实用指南:更新版》。
J Cutan Med Surg. 2022 Sep-Oct;26(2_suppl):2S-24S. doi: 10.1177/12034754221116115. Epub 2022 Aug 24.
8
Hidradenitis suppurativa.化脓性汗腺炎
Presse Med. 2010 Dec;39(12):1254-64. doi: 10.1016/j.lpm.2010.08.003. Epub 2010 Oct 20.
9
Hidradenitis suppurativa - Management, comorbidities and monitoring.化脓性汗腺炎——管理、合并症与监测
Aust Fam Physician. 2017;46(8):584-588.
10
[CME Dermatology 23/Answers: Hidradenitis suppurativa].[继续医学教育皮肤科23/答案:化脓性汗腺炎]
Praxis (Bern 1994). 2021 Jun;110(8):471-472. doi: 10.1024/1661-8157/a003694.

引用本文的文献

1
Management and Burden of Hidradenitis Suppurativa: An Italian Hybrid Real-World Study.化脓性汗腺炎的管理与负担:一项意大利混合现实世界研究。
Dermatol Ther (Heidelb). 2025 May 9. doi: 10.1007/s13555-025-01407-0.
2
Interleukin-17 Inhibitors in the Treatment of Hidradenitis Suppurativa.白细胞介素-17抑制剂在化脓性汗腺炎治疗中的应用
BioDrugs. 2025 Jan;39(1):53-74. doi: 10.1007/s40259-024-00687-w. Epub 2024 Nov 28.